超重与肥胖患者不同肾功能下万古霉素AUC 400-600 mg·h/L靶向给药方案
该研究基于210例超重/肥胖患者1188份治疗药物监测浓度及20例减重手术肥胖者207份 rich 浓度数据,建立群体PK模型并模拟AUC24 400-600 mg·h/L靶向给药方案;万古霉素清除率随总重量线性增加、随CKD-EPI肾功能幂函数增加,ICU患者清除率低15.5%;前48小时需给负荷剂量,维持剂量需按总重量、肾功能及ICU状态调整。
要点
- 万古霉素清除率随总重量线性增加并随CKD-EPI肾功能幂函数增加,ICU患者清除率低15.5%。
- 达标AUC24 400-600 mg·h/L时,前48小时连续或间歇给药均需给予负荷剂量。
- 维持剂量需根据总重量、肾功能和ICU入住状态调整。
核心结论
- 超重和肥胖患者万古霉素维持剂量应综合考虑肾功能、总重量和ICU入住状态以实现安全有效暴露。
研究设计与样本
- 群体药代动力学研究,使用NONMEM 7.4建模,纳入210例超重/肥胖患者1188份TDM浓度及20例减重手术肥胖者207份rich浓度数据。
主要发现
- 万古霉素清除率随总重量线性增加,随CKD-EPI肾功能呈幂函数增加。
- ICU患者万古霉素清除率较非ICU患者低15.5%。
- 模拟显示前48小时达到AUC24 400-600 mg·h/L需给予两个负荷剂量。
- 按模型推荐给药后中位AUC24从治疗开始即处于目标范围内。
关键数值与推荐
- 目标AUC24为400-600 mg·h/L。
- 负荷剂量方案需给予两个负荷剂量(连续输注和间歇给药均如此)。
- 维持剂量需根据总重量、肾功能和ICU入住状态调整。
临床怎么用
- 对超重/肥胖患者启动万古霉素时,前48小时给予两个负荷剂量以尽快达到AUC24 400-600 mg·h/L。
- 维持剂量根据总重量、CKD-EPI肾功能及是否ICU入住进行个体化调整。
- 利用AUC靶向监测确保疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The latest vancomycin guideline recommends area under the curve (AUC)-targeted dosing and monitoring for efficacy and safety. However, guidelines for AUC-targeted starting dosing in patients with obesity and/or renal insufficiency are currently lacking. This study quantifies the pharmacokinetics (PK) of vancomycin in this population and provides AUC-targeted dosing recommendations. METHODS: Vancomycin concentrations (n = 1188) from therapeutic drug monitoring of 210 overweight and obese patients with varying degrees of renal (dys)function from the ward (74.8%) and intensive care unit (ICU, 25.2%) were pooled with published rich concentration-time data (n = 207) from 20 (morbidly) obese subjects undergoing bariatric surgery. A population model was developed using NONMEM 7.4. Stochastic simulations were performed to design dosing guidelines targeting an AUC24 between 400-600 mg·h/L. RESULTS: Vancomycin clearance (CL) was found to increase linearly with total bodyweight and with renal function (CKD-EPI) in a power relation. Additionally, CL proved 15.5% lower in ICU patients. Our model shows that, to reach the target AUC between 400 and 600 mg·h/L in the first 48 h, two loading doses are required for both continuous infusion and intermittent dosing regimens. Maintenance doses were found to require adjustment for total bodyweight, renal function, and ICU admission status. With this guideline, the median AUC24 is well within the target from the start of the treatment onwards. CONCLUSIONS: To achieve safe and effective vancomycin exposure for maintenance doses in overweight and obese patients, renal function, total bodyweight, and ICU admission status should be taken into account. TRIAL REGISTRATION: The AMIGO trial was registered in the Dutch Trial Registry [NTR6058].
引用
- Zhang T, Krekels EHJ, Smit C, et al. How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400-600 mg·h/L-Targeted Dosing. Clin Pharmacokinet. 2023. PMID: 37971650. doi:10.1007/s40262-023-01324-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。